Relevance of DELFI 2019 internally cross-validated cancer detection protocol to "Select a plasma ctDNA fragmentomics detection workflow"
- Use case
- Select a plasma ctDNA fragmentomics detection workflow
- Assessed by
- DELFI 2019 internally cross-validated cancer detection protocol
- Relevance
- Proxy evidence
- Endpoint
- Sensitivity (73%, 152/208) at a reported 98% specificity for plasma cfDNA fragmentomics-based cancer detection, repeated 10-fold cross-validation (10 repeats)
A repeated 10-fold cross-validation (10 repeats) on one assembled cohort is a proxy for the broader plasma ctDNA fragmentomics detection decision and for this explicitly assessed assay endpoint; it is internal cross-validation, not a separately held-out validation cohort and not prospective screening validation.
1 reviewed evaluation
Evidence
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Evidence table
Inspect claims, sources and review details
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
15 evidence rows matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|---|---|
Citation locations1 values
| Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252 amp-20261007-ctdna-fragmentomics-source: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/ Version: Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record Format: curator_factual_receipt |
Constraints2 values
| Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252 amp-20261007-ctdna-fragmentomics-source: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/ Version: Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record Format: curator_factual_receipt |
| Endpoint Sensitivity (73%, 152/208) at a reported 98% specificity for plasma cfDNA fragmentomics-based cancer detection, repeated 10-fold cross-validation (10 repeats) Context-only references | Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252 amp-20261007-ctdna-fragmentomics-source: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/ Version: Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record Format: curator_factual_receipt |
| Claimed field links:assessed_by:amp-20261007-ctdna-fragmentomics-protocol Context-only references | Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252 amp-20261007-ctdna-fragmentomics-source: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/ Version: Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record Format: curator_factual_receipt |
Limitations5 values
| Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252 amp-20261007-ctdna-fragmentomics-source: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/ Version: Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record Format: curator_factual_receipt |
Pinned records5 values
| Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252 amp-20261007-ctdna-fragmentomics-source: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/ Version: Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record Format: curator_factual_receipt |
| Rationale A repeated 10-fold cross-validation (10 repeats) on one assembled cohort is a proxy for the broader plasma ctDNA fragmentomics detection decision and for this explicitly assessed assay endpoint; it is internal cross-validation, not a separately held-out validation cohort and not prospective screening validation. Context-only references | Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252 amp-20261007-ctdna-fragmentomics-source: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/ Version: Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record Format: curator_factual_receipt |
| Reason Add Codex-checked primary-source protocol evidence from the bounded AMP intake (rewire.it#365). Context-only references | Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252 amp-20261007-ctdna-fragmentomics-source: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/ Version: Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record Format: curator_factual_receipt |
| Relevance proxy Context-only references | Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252 amp-20261007-ctdna-fragmentomics-source: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/ Version: Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record Format: curator_factual_receipt |
| Revision 1 Context-only references | Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252 amp-20261007-ctdna-fragmentomics-source: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/ Version: Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record Format: curator_factual_receipt |
Sources and history
Release 2026-11-21-c8bea25e5abb · Record review: source checked
1 source record and release history
- Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252 · Original source · Cristiano et al., Nature 570, 385–389 (2019), author manuscript PMC6774252
Technical metadata and extraction receipts
Stable ID: use-case-mapping-amp-20261007-issue15
- field
- links:assessed_by:amp-20261007-ctdna-fragmentomics-protocol
- value
- amp-20261007-ctdna-fragmentomics-protocol
- relevance
- proxy
- endpoint
- Sensitivity (73%, 152/208) at a reported 98% specificity for plasma cfDNA fragmentomics-based cancer detection, repeated 10-fold cross-validation (10 repeats)
- rationale
- A repeated 10-fold cross-validation (10 repeats) on one assembled cohort is a proxy for the broader plasma ctDNA fragmentomics detection decision and for this explicitly assessed assay endpoint; it is internal cross-validation, not a separately held-out validation cohort and not prospective screening validation.
- constraints
- Inspect every linked evaluation's source locator and preserved conflicts before citing a result.; Do not combine this mapping's evaluations with any other protocol's results.
- limitations
- 4 of 215 healthy individuals misclassified at source-labelled 98% specificity. Retain rounded printed specificity; do not recompute sensitivity.; Internal repeated cross-validation is not independent prospective screening validation; clinically identified cancers and healthy comparators differ from intended screening population.; DELFI composite features include CNAs/mtDNA, so this exact result is not pure fragmentation alone.; cfDNA signal is not purified ctDNA, tumour fraction limit is unreported for this endpoint.; Combined mutation+DELFI 115/126 (91%) is a different subset/configuration and is excluded.
- revision
- 1
- reason
- Add Codex-checked primary-source protocol evidence from the bounded AMP intake (rewire.it#365).
- citation locators
- source id: amp-20261007-ctdna-fragmentomics-source; locator: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/
- source locator
- amp-20261007-ctdna-fragmentomics-source: See clinical/claims.csv and clinical/sources.md in data/omics/use-case-coverage-amp-20261007/
- review
- method: automated-source-review; reviewer: codex; claude-sonnet; reviewer note: Claude Sonnet AMP-integration worker, bounded transcription of Codex-checked primary values; independently reviewed by Codex (workbench/amp-supervision/primary-review.md, integration-review-corrections.md); reviewed at: 2026-10-07T13:38:59Z; note: Bounded primary-source transcription, independently Codex-checked. No new model execution, independent experimental reproduction, qualified human scientific review or clinical validation.
- reviewed evaluations
- amp-20261007-ctdna-fragmentomics-evaluation
- pins
- record id: amp-20261007-ctdna-fragmentomics-evaluation; fields: status; links; attributes.origin; attributes.comparison; sha256: a79d0eab434ea82303e0d9a5183c1189f5b2aa218bf353fc33b380fdc913c608; record id: amp-20261007-ctdna-fragmentomics-protocol; fields: status; name; description; facets; source_ids; links; attributes; sha256: 2c598a384f147b78f0491c9b7f083bc9e08cca23f0b30360068152b8eaf4655e; record id: amp-20261007-ctdna-fragmentomics-result; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: d88dadfae8f33129a005dbc31526216aa8e8aa3b7da4d261f9078985d1ac4790; record id: amp-20261007-ctdna-fragmentomics-source; fields: status; attributes.artifact_sha256; sha256: ce4591cb119aea1a3cd4d020dc50a2b61c919728f3bb69eb047e265b3e591716; record id: use-case-plasma-ctdna-fragmentomics; fields: status; name; description; facets; attributes.question; attributes.decision; attributes.inputs; attributes.output; attributes.exclusions; attributes.setting; attributes.clinical_scope; attributes.intended_users; sha256: 01d27c2ce64a391055bddc6dec9d5db208df9bee3d5e679045dd3f4f04a0ca08